Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1
- PMID: 11793011
- DOI: 10.1038/nature711
Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1
Abstract
Neurofibromatosis type I (NF1) is one of the most common single-gene disorders that causes learning deficits in humans. Mice carrying a heterozygous null mutation of the Nfl gene (Nfl(+/-) show important features of the learning deficits associated with NF1 (ref. 2). Although neurofibromin has several known properties and functions, including Ras GTPase-activating protein activity, adenylyl cyclase modulation and microtubule binding, it is unclear which of these are essential for learning in mice and humans. Here we show that the learning deficits of Nf1(+/-) mice can be rescued by genetic and pharmacological manipulations that decrease Ras function. We also show that the Nf1(+/-) mice have increased GABA (gamma-amino butyric acid)-mediated inhibition and specific deficits in long-term potentiation, both of which can be reversed by decreasing Ras function. Our results indicate that the learning deficits associated with NF1 may be caused by excessive Ras activity, which leads to impairments in long-term potentiation caused by increased GABA-mediated inhibition. Our findings have implications for the development of treatments for learning deficits associated with NF1.
Similar articles
-
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.Curr Biol. 2005 Nov 8;15(21):1961-7. doi: 10.1016/j.cub.2005.09.043. Curr Biol. 2005. PMID: 16271875
-
A mouse model for the learning and memory deficits associated with neurofibromatosis type I.Nat Genet. 1997 Mar;15(3):281-4. doi: 10.1038/ng0397-281. Nat Genet. 1997. PMID: 9054942
-
NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.Circulation. 2007 Nov 6;116(19):2148-56. doi: 10.1161/CIRCULATIONAHA.107.707752. Epub 2007 Oct 22. Circulation. 2007. PMID: 17967772
-
Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1.J Child Neurol. 2002 Aug;17(8):622-6; discussion 627-9, 646-51. doi: 10.1177/088307380201700813. J Child Neurol. 2002. PMID: 12403561 Review.
-
Recent developments in neurofibromatosis type 1.Curr Opin Neurol. 2007 Apr;20(2):135-41. doi: 10.1097/WCO.0b013e3280895da8. Curr Opin Neurol. 2007. PMID: 17351482 Review.
Cited by
-
Interactions between Ras and Rap signaling pathways during neurodevelopment in health and disease.Front Mol Neurosci. 2024 Feb 23;17:1352731. doi: 10.3389/fnmol.2024.1352731. eCollection 2024. Front Mol Neurosci. 2024. PMID: 38463630 Free PMC article. Review.
-
Transcranial Direct Current Stimulation in neurogenetic syndromes: new treatment perspectives for Down syndrome?Front Cell Neurosci. 2024 Feb 22;18:1328963. doi: 10.3389/fncel.2024.1328963. eCollection 2024. Front Cell Neurosci. 2024. PMID: 38456063 Free PMC article.
-
Rescue of sharp wave-ripples and prevention of network hyperexcitability in the ventral but not the dorsal hippocampus of a rat model of fragile X syndrome.Front Cell Neurosci. 2023 Dec 1;17:1296235. doi: 10.3389/fncel.2023.1296235. eCollection 2023. Front Cell Neurosci. 2023. PMID: 38107412 Free PMC article.
-
The efficacy of statins for improving cognitive impairments in pediatric patients with neurofibromatosis type 1 (NF-1): a meta-analysis.Front Pediatr. 2023 Oct 9;11:1274972. doi: 10.3389/fped.2023.1274972. eCollection 2023. Front Pediatr. 2023. PMID: 37876519 Free PMC article. Review.
-
Statins in Children with Neurofibromatosis Type 1: A Systematic Review of Randomized Controlled Trials.Children (Basel). 2023 Sep 15;10(9):1556. doi: 10.3390/children10091556. Children (Basel). 2023. PMID: 37761518 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
